A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan
Modern Rheumatology · 06.07.2024 · 34 (4) · 775-783
DOI: 10.1093/mr/road074 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, online erschienen am 31.07.2023. Verfasst von Masayoshi Harigai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
In clinical trials, tocilizumab (TCZ) is efficacious in patients with giant cell arteritis (GCA). This study evaluated the real-world tolerability and effectiveness of TCZ in Japanese patients with GCA.
Methods
In this multicentre, prospective, Phase 4, large-scale, observational study, patients with GCA (with no TCZ treatment 6 months before the study) were recruited from 71 centres across Japan. Patients received subcutaneous TCZ 162 mg weekly (observation period, 52 weeks).
Results
Of the 117 patients [female, 70.1%; mean age, 74.2 years; mean disease duration, 1.4 years; treated for new-onset GCA, 71.8%; presence of large-vessel lesions (LVLs), 61.5%; previous immunosuppressant use, 28.2%; glucocorticoids at baseline, 95.7% (mean: 22.4 mg/day)], 38.5% reported adverse events. The most common adverse events of special interest were neutropaenia and leukopaenia (7.7%), followed by serious infection (6.0%). The relapse-free proportion was 85.0%; relapse after remission, 6.0%; and no remission, 9.0%. At the last observation, 94.2% of relapse-free patients received a concomitant glucocorticoid dose of <10 mg/day. Fatigue, headache, neck pain, and absence of LVLs were positively associated with the relapse.
Conclusions
TCZ was effective and well tolerated in Japanese patients with GCA and may be an effective treatment option combined with glucocorticoids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Risk Communication Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
- Safety Science Department, Drug Safety Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
- Specialty Medical Science Department, Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
- Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
ORCID-Profile: Masayoshi Harigai, Yoshikazu Nakaoka
Zitieren
APA
Harigai, M., Miyamae, T., Hashimoto, H., Umetsu, K., Yamashita, K., & Nakaoka, Y. (2024). A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Modern Rheumatology, 34(4), 775-783. https://doi.org/10.1093/mr/road074
Vancouver
Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Modern Rheumatology. 2024;34(4):775-783. doi:10.1093/mr/road074
BibTeX
@article{Harigai2024,
author = {Harigai, Masayoshi and Miyamae, Takako and Hashimoto, Hideyuki and Umetsu, Kosei and Yamashita, Katsuhisa and Nakaoka, Yoshikazu},
title = {A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan},
journal = {Modern Rheumatology},
year = {2024},
volume = {34},
number = {4},
pages = {775--783},
doi = {10.1093/mr/road074}
}
EUVIMED